Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Moehler, Markus, Janjigian, Yelena, Al-Batran, Salah-Eddin, Wainberg, Zev, Van Cutsem, Eric, Molena, Daniela, Muro, Kei, Hyung, Woo Jin, Wyrwicz, Lucjan, Oh, Do-Youn, Omori, Takeshi, Garrido, Marcelo, Sousa, Oliveira Sulene Cunha, Liberman, Moishe, Oliden, Victor Castro, Bilici, Mehmet, Kurland, John F., Xynos, Ioannis, Mann, Helen, Tabernero, Josep